.Pharmacolibrary.Drugs.ATC.B.B01AB10 .Pharmacolibrary.Drugs.ATC.B.B01AB10| name: | Tinzaparin |
| ATC code: | B01AB10 | route: | subcutaneous |
| n-compartments | 1 |
Tinzaparin is a low molecular weight heparin (LMWH) used for the prevention and treatment of deep vein thrombosis and pulmonary embolism. It is administered parenterally and is approved for clinical use.
Pharmacokinetic parameters in healthy adult volunteers, both sexes, after subcutaneous administration.
Gouin-Thibault, I, et al., & Delavenne, X (2024). Tinzaparin, an alternative to subcutaneous unfractionated heparin, in patients with severe and end-stage renal impairment: a retrospective observational single-center study. Journal of thrombosis and haemostasis : JTH 22(10) 2864–2872. DOI:10.1016/j.jtha.2024.07.006 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39019439
Barrett, JS, et al., & Gastonguay, M (2001). Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis. International journal of clinical pharmacology and therapeutics 39(10) 431–446. PUBMED:https://pubmed.ncbi.nlm.nih.gov/11680668
Hainer, JW, et al., & Hua, TA (2002). Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis. American journal of kidney diseases : the official journal of the National Kidney Foundation 40(3) 531–538. DOI:10.1053/ajkd.2002.34911 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12200805